Plasma prolactin and prostate cancer risk: A prospective study

Area of Science:

• Endocrinology
• Oncology
• Urology

Background:

• Prolactin, a pituitary hormone, stimulates prostate growth in experimental models.
• Prolactin receptors are found in human prostate tissue, including pre-cancerous lesions, suggesting a potential role in prostate cancer.
• Previous research indicates a possible association between prolactin and prostate cancer development.

Purpose of the Study:

• To investigate the hypothesis that elevated circulating prolactin levels are associated with an increased risk of prostate cancer.
• To determine if prolactin plays a role in the development of prostate cancer.

Main Methods:

• A case-control study was conducted within the Northern Sweden Health and Disease Cohort.
• Plasma samples from 144 men diagnosed with prostate cancer and 289 matched controls were analyzed for prolactin levels.
• Statistical analyses, including univariate regression and adjustments for covariates like testosterone and IGFs, were performed.

Main Results:

• No significant association was found between plasma prolactin levels and prostate cancer risk in univariate analysis.
• Odds ratios for prostate cancer across increasing quartiles of prolactin were consistently close to 1.0.
• Adjusting for height, weight, testosterone, sex hormone-binding globulin, IGF-I, and IGF-binding protein-3 did not alter the risk estimates.

Conclusions:

• Elevated circulating prolactin levels are not related to an increased risk of prostate cancer.
• High circulating prolactin is not associated with the development of prostate cancer.
• The findings do not support a role for prolactin in prostate cancer etiology.